Cutter & CO Brokerage Inc. trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 0.8% during the third quarter, Holdings Channel reports. The institutional investor owned 281,795 shares of the company’s stock after selling 2,383 shares during the period. Novo Nordisk A/S makes up about 7.6% of Cutter & CO Brokerage Inc.’s holdings, making the stock its 2nd largest position. Cutter & CO Brokerage Inc.’s holdings in Novo Nordisk A/S were worth $33,553,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. 1620 Investment Advisors Inc. acquired a new position in Novo Nordisk A/S during the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Novo Nordisk A/S during the first quarter valued at approximately $26,000. Orion Capital Management LLC bought a new stake in Novo Nordisk A/S during the first quarter worth approximately $26,000. Finally, Gilliland Jeter Wealth Management LLC grew its position in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S Stock Down 0.1 %
Novo Nordisk A/S stock traded down $0.12 during mid-day trading on Tuesday, hitting $112.24. The company’s stock had a trading volume of 387,480 shares, compared to its average volume of 4,274,362. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a market cap of $503.68 billion, a PE ratio of 38.49, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. The firm’s 50 day moving average is $126.16 and its 200 day moving average is $131.28.
Novo Nordisk A/S Cuts Dividend
The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.66%.
Analysts Set New Price Targets
A number of brokerages recently issued reports on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, October 10th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.50.
View Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also
- Five stocks we like better than Novo Nordisk A/S
- How to Calculate Stock Profit
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- The 3 Best Fintech Stocks to Buy Now
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks Reporting Kitchen Sink Quarters to Usher in a Turnaround
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.